Serono, NovImmune end autoimmune deal
NovImmune has licensed Serono exclusive worldwide rights to two of its fully human monoclonal antibodies for autoimmune disease indications. The candidates, NI-0401 and NI-0501, are currently in preclinical trials.
- Large Molecule
- Includes Equity
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.